Thus, in principle, a tumor cell-directed STINGa ADC could deliver payload and activate STING signaling in cancer cells and in tumor-resident myeloid cells, while sparing tumor-resident B and T cells as well as normal tissues. This evidence concerns the gene STING1 and cancer.